Skip to main content
. 2023 Mar 31;23:197. doi: 10.1186/s12879-023-08172-5

Table 2.

Post-COVID neuropsychological manifestations 12 weeks after the primary COVID-19

Symptom Fluvoxamine (n = 42) Placebo (n = 43) P-value* Relative Risk
Primary outcome
 Fatigue 9 (21.4%) 19 (44.2%) 0.026 0.48 (0.25–0.95)
Secondary outcome
 Headache 3 (7.1%) 6 (14%) 0.483 0.51 (0.14–1.91)
 Memory impairment 2 (4.8%) 5 (11.6%) 0.433 0.41 (0.08–1.99)
 Poor concentration 8 (19%) 7 (16.3%) 0.738 1.17 (0.46–2.93)
 Insomnia 9 (21.4%) 10 (23.3%) 0.840 0.92 (0.41–2.03)
 Aggression 1 (2.4%) 4 (9.3%) 0.360 0.25 (0.03–2.19)
 Anxiety 8 (19%) 13 (30.2%) 0.232 0.63 (0.29–1.36)
 Depression 1 (2.4%) 7 (16.3%) 0.058 0.14 (0.02–1.13)
 Distorted Taste 3 (7.1%) 8 (18.6%) 0.115 0.38 (0.11–1.34)
 Distorted Smell 6 (14.3%) 11 (25.6%) 0.193 0.56 (0.22–1.37)
 Myalgia 5 (11.9%) 7 (16.3%) 0.563 0.73 (0.25–2.12)
 PCS 32 (76.2%) 35 (81.4%) 0.557 0.93 (0.75–1.16)

PCS Post-COVID syndrome

* Statistically significant p-values are bolded